Based on data from the TCGA-BC cohort, the higher expression of RBM15B (p = 0.014, 95% confidence interval: 0.48–0.94) significantly correlated with favorable overall survival (OS), whereas the high expression of KIAA1429 (p = 0.032, 95% confidence interval: 1.03–1.96) and METTL16 (p = 0.02, 95% confidence interval: 1.06–2.02) correlated with poor OS. Here, VIRMA is linked to breast cancer.